Valuation: PTC Therapeutics, Inc.

Market Cap 6.08B 5.25B 4.93B 4.49B 8.44B 582B 8.55B 57.75B 22.63B 291B 22.84B 22.34B 969B P/E 2026 *
47.7x
P/E 2027 * 27x
Enterprise Value 4.21B 3.64B 3.41B 3.11B 5.84B 403B 5.92B 39.99B 15.67B 202B 15.81B 15.47B 671B EV / Sales 2026 *
3.35x
EV / Sales 2027 * 2.87x
Free-Float
92.61%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: PTC Therapeutics, Inc.

1 day+1.65%
1 week-2.34%
Current month+7.16%
1 month-7.27%
3 months+1.97%
6 months+5.36%
Current year-4.05%
1 week 70.85
Extreme 70.85
74.22
1 month 64.57
Extreme 64.5675
80.56
Current year 61.43
Extreme 61.43
90.87
1 year 48.09
Extreme 48.09
90.87
3 years 17.53
Extreme 17.53
90.87
5 years 17.53
Extreme 17.53
90.87
10 years 4.03
Extreme 4.03
90.87
Manager TitleAgeSince
Chief Executive Officer 54 21/03/2023
Director of Finance/CFO 41 12/07/2023
Chief Tech/Sci/R&D Officer - 30/09/2017
Director TitleAgeSince
Chairman 74 31/10/2004
Chairman 80 30/03/1998
Director/Board Member 65 30/11/2005
Date Insider Type Main position Quantity % Market Cap.
04/08/26 Sell

Chief Executive Officer

-10,292 0.0124%
28/07/26 Other

Director

200,401 0.2416%
28/07/26 Free

Director

11,213 0.0135%
Change 5-day change 1-year change 3-year change Capi.($)
+1.65%-2.34%+49.28%+82.20% 5.98B
+0.25%-3.96%+68.73%+120.06% 1,052B
+0.78%+0.21%+48.53%+50.78% 627B
+0.35%+0.95%+21.11%+66.86% 441B
+0.28%-4.56%+39.10%+38.05% 349B
+0.78%-2.68%+24.03%+37.32% 287B
+0.87%-3.59%-0.28%+7.12% 241B
+1.00%+0.52%+41.46%+58.95% 224B
-0.78%-4.49%-10.28%-54.13% 202B
+0.40%+4.40%+17.36%+81.59% 172B
Average +0.56%-1.31%+29.91%+48.88% 360.12B
Weighted average by Cap. +0.44%-1.70%+39.72%+63.91%

Financials

2026 *2027 *
Net sales 1.26B 1.08B 1.02B 926M 1.74B 120B 1.77B 11.92B 4.67B 60.14B 4.71B 4.61B 200B 1.37B 1.18B 1.11B 1.01B 1.9B 131B 1.93B 13B 5.1B 65.61B 5.14B 5.03B 218B
Net income 144M 125M 117M 106M 200M 13.79B 203M 1.37B 537M 6.91B 542M 530M 22.99B 216M 187M 175M 160M 300M 20.69B 304M 2.05B 805M 10.37B 812M 795M 34.48B
Net Debt -1.87B -1.62B -1.52B -1.38B -2.6B -179B -2.63B -17.76B -6.96B -89.63B -7.02B -6.87B -298B -2.15B -1.85B -1.74B -1.58B -2.98B -205B -3.02B -20.37B -7.98B -103B -8.05B -7.88B -342B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
17/08/26 US$72.88 +1.65% 985,767
14/08/26 US$71.70 -0.38% 564,330
13/08/26 US$71.97 -0.92% 697,348
12/08/26 US$72.64 -1.44% 976,043
11/08/26 US$73.70 -1.25% 763,594
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
72.88USD
Average target price
99.29USD
Spread / Average Target
+36.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock